| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
TLR4-NF-κB signaling pathway; Helicobacter pylori (antimicrobial target).
|
|---|---|
| ln Vitro |
2-(Hydroxymethyl)anthraquinone exhibits strong activity against Helicobacter pylori ATCC 43504 at 0.01 mg/disc in the paper disc diffusion assay. It attenuates lipopolysaccharide-induced pulmonary edema, myeloperoxidase activity, and inflammatory cytokine production. It suppresses the production of NO, TGF-β1, TNF-α, IL-6, and IL-1β in LPS-stimulated RAW 264.7 macrophage cells. It antagonizes TLR4 expression and NF-κB activation.
|
| ln Vivo |
In vivo studies show that 2-(hydroxymethyl)anthraquinone attenuates lipopolysaccharide-induced pulmonary edema. It reduces myeloperoxidase activity and inflammatory cytokine production in vivo. Its anti-inflammatory effects are mediated through the TLR4-NF-κB pathway. These properties suggest potential therapeutic applications for inflammatory conditions, particularly those involving LPS-induced inflammation.
|
| Enzyme Assay |
Paper disc diffusion assay: sterile filter paper discs impregnated with the test compound (0.01 mg/disc) are placed on agar plates inoculated with Helicobacter pylori ATCC 43504. After incubation, the zone of inhibition around each disc is measured. For anti-inflammatory studies, LPS-stimulated RAW 264.7 macrophage cells are treated with the compound and cytokine levels are measured by ELISA. TLR4 and NF-κB expression are assessed by Western blot.
|
| Cell Assay |
RAW 264.7 macrophage cells are cultured in appropriate medium and stimulated with lipopolysaccharide (LPS) to induce inflammation. Cells are treated with 2-(hydroxymethyl)anthraquinone at various concentrations. Culture supernatants are collected and levels of inflammatory cytokines (NO, TGF-β1, TNF-α, IL-6, IL-1β) are measured by ELISA. Cell lysates are prepared for Western blot analysis of TLR4 and NF-κB expression. Cell viability is assessed using MTT assay.
|
| Animal Protocol |
For in vivo anti-inflammatory studies, animal models such as LPS-induced pulmonary edema models are used. Mice are administered LPS via intratracheal instillation to induce pulmonary inflammation. The test compound is administered before or after LPS challenge. Lung tissues are collected for assessment of edema, myeloperoxidase activity, and inflammatory cytokine levels. Histological examination of lung tissues is performed to evaluate inflammation.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for 2-(hydroxymethyl)anthraquinone are limited. As an anthraquinone derivative, it is expected to have moderate lipophilicity. The compound has a melting point of 192-197°C and an assay purity of 95-100%. It is used as a photoremovable protecting group (PRPG) that can be activated by light to release caged compounds. This property is utilized in chemical biology applications for controlled release of bioactive molecules.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for 2-(hydroxymethyl)anthraquinone are limited. Anthraquinone derivatives generally require careful handling as some may have genotoxic or carcinogenic potential. The compound exhibits antimicrobial activity against H. pylori, indicating biological activity at low concentrations. Standard laboratory safety practices should be followed when handling this compound. It is intended for research use only.
|
| References | |
| Additional Infomation |
2-(hydroxymethyl)anthraquinone is an anthraquinone compound and a metabolite. It has been reported that Rubia cordifolia and Grewia globosum contain 2-(hydroxymethyl)anthraquinone, and relevant data are available for reference.
2-(Hydroxymethyl)anthraquinone is a versatile compound with dual applications in chemical biology and pharmacology. As a photoremovable protecting group (PRPG), it is used to chemically cage sex pheromones for controlled release studies. Its anti-inflammatory and antimicrobial properties make it of interest for therapeutic research. The compound is found in natural sources such as Tabebuia impetiginosa (taheebo) and is used in analytical and research applications. It is for research use only. |
| Molecular Formula |
C15H10O3
|
|---|---|
| Molecular Weight |
238.24
|
| Exact Mass |
238.062
|
| CAS # |
17241-59-7
|
| PubChem CID |
87014
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
472.9±34.0 °C at 760 mmHg
|
| Melting Point |
192-197 °C(lit.)
|
| Flash Point |
253.9±22.2 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.677
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
18
|
| Complexity |
363
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C=C(C=C3)CO
|
| InChi Key |
JYKHAJGLEVKEAA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O3/c16-8-9-5-6-12-13(7-9)15(18)11-4-2-1-3-10(11)14(12)17/h1-7,16H,8H2
|
| Chemical Name |
2-(hydroxymethyl)anthracene-9,10-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (419.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1974 mL | 20.9872 mL | 41.9745 mL | |
| 5 mM | 0.8395 mL | 4.1974 mL | 8.3949 mL | |
| 10 mM | 0.4197 mL | 2.0987 mL | 4.1974 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
